
500-mg (white, film-coated, oval, biconvex, scored on one side, and labeled OV 111)
Sabril (SAB-reel) is the brand name used in the United States and some other countries for the seizure medicine vigabatrin (vi-GAB-a-trin). In the United States, the Food and Drug Administration (FDA) first approved vigabatrin in 2009. In 2020, it's indication was expanded for treatment of focal epilepsy at different ages. It has been available in other countries for decades. In the U.S. it is now approved for use for:
Sabril is marketed in the United States by Lundbeck. Because of the possibility of permanent vision loss, the drug can only be prescribed by physicians who have pre-enrolled in a program to use Sabril. This program, known as the Sabril REMS Program (updated as of July 21, 2016) is able to help health care providers who prescribe the drug. Sabril can be obtained through certain specialty and inpatient pharmacies.
Information and help for providers prescribing Sabril and for people who may take the medication is available at www.Sabril.net or by calling Sabril REMS Program at 1-888-457-4273). Any side effects that suggest vision loss should be reported to your doctor and the Sabril REMS Program. If you take a Sabril prescription into a regular pharmacy, it will NOT be filled.
The SharePlus Reimbursement Support Program by Lundbeck offers help people with questions about insurance coverage, reimbursement-related issues, and coordination with specialty pharmacies. Contact 1-888-457-4273 in the U.S for assistance.